Compare Enveric Biosciences Inc (ENVB) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Raymond James Financial, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Raymond James Financial, Inc. trades at $158.14 (market cap $30.25B). The key difference: Raymond James Financial, Inc. is far larger — about 4521.7× Enveric Biosciences Inc's market cap, and Raymond James Financial, Inc. pays a 1.37% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Raymond James Financial, Inc. for 74 Days on average.
| ENVB | RJF | |
|---|---|---|
Market Cap | $6.69M | $30.25B |
Volume | 41,141 | 1,288,635 |
Sector | Health | Financials |
52-Week High | $10.80 | $181.18 |
52-Week Low | $1.27 | $140.89 |
Typical Hold Time | 14 Days | 74 Days |
Enterprise Value | -$1.60M | $24.12B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Raymond James Financial (RJF) trades at $158.6, down 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.14, and maintains solid fundamentals including a P/E of 13.71 and ROE of 18.48%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical weakness and high investing cash outflows pose risks. Revenue growth and margin stability support long-term value, though market volatility and expense pressures remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
